Company Overview
OPKO Health, Inc. operates as a healthcare company with a physical presence in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally, functioning primarily within the Diagnostics & Research industry. The organization focuses on two distinct segments, specifically the Pharmaceutical and Diagnostics sectors, where the Pharmaceutical segment is dedicated to developing specific antibody technologies like MDX2001, a tetra-specific antibody targeting several types of conditions. This entity currently supports a workforce of 2,275 employees and maintains a market capitalization of $859.75M while generating total revenue of $606.88M over the trailing twelve-month period. These valuation and revenue figures position the company as a mid-to-large cap player within the healthcare sector, suggesting significant operational scale despite the specific challenges inherent in its current financial performance.
Financial Health
The company reported a revenue of $606.88M for the trailing twelve months, yet this gross income was significantly eroded to produce a net income of $-225,680,000 and an EBITDA of $-127,358,000. The substantial gap between the $606.88M in revenue and the negative net income reveals a cost structure where operating expenses, likely driven by research and development or general administrative costs, exceed the gross profit generated by sales by a wide margin. Furthermore, the free cash flow stands at $-131,252,376, indicating that the company is currently burning cash rather than generating liquidity from its operations, which limits its immediate financial flexibility without external capital raises or asset sales. Analyzing the three primary margins shows a Gross Margin of 13.5%, an Operating Margin of -29.0%, and a Profit Margin of -37.2%, where the low gross margin suggests pricing pressures or high cost of goods sold, while the deeply negative operating and profit margins confirm that overhead costs are consuming the majority of revenue. Regarding balance sheet strength, the company holds $364.41M in cash against $396.78M in debt, resulting in a Debt to Equity ratio of 31.29, which indicates a highly leveraged position where liabilities significantly outweigh equity. Although the current ratio of 3.97 suggests a theoretically strong ability to cover short-term obligations with current assets, the underlying negative cash flow and high debt load create a fragile liquidity profile. Additionally, the Return on Equity is -17.1% and the Return on Assets is -6.6%, metrics that reveal management is currently destroying shareholder value and failing to generate efficient returns on the capital base employed in the business.
Valuation Assessment
The valuation metrics present a complex picture, with a P/E Ratio (TTM) listed as N/A due to losses, while the Forward P/E is calculated at -3.39. The difference between a non-existent trailing earnings multiple and a negative forward multiple implies that the market is pricing in a continued period of negative earnings rather than an immediate return to profitability. The Price to Book ratio stands at 0.67, which indicates that the company is trading at a discount relative to its book value, suggesting the market values the firm at less than the net assets recorded on its balance sheet. Alternative valuation measures include a Price to Sales ratio of 1.42 and an EV/EBITDA of -6.93, which suggest the stock is being valued based on revenue multiples rather than earnings, a common practice for loss-making biotech or pharmaceutical firms. In terms of trading range, the 52-Week High is $1.83 and the 52-Week Low is $1.10, placing the current trading environment within a narrow band where the stock has experienced volatility of approximately 40% between its yearly extremes. The Beta of 1.52 indicates that the stock's price volatility is significantly higher than the broader market, moving with greater intensity than the S&P 500 during periods of market stress or rally.
Growth & Income
The growth profile for the company is characterized by a Revenue Growth (YoY) of -19.2% and an Earnings Growth (YoY) of N/A due to the absence of earnings. Since there are no positive earnings, the comparison of earnings growth versus revenue growth is not applicable in a traditional sense, but the decline in revenue indicates a contraction in the top line that is directly impacting the bottom line. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio to shareholders, effectively meaning that all available cash flow is retained internally rather than distributed. This retention strategy suggests the company is not currently prioritizing income generation for investors but is instead focused on preserving capital to fund its operations and research initiatives. Overall, the growth and income profile for OPKO Health, Inc. reflects a period of financial contraction and retention, where the business is scaling back revenue without distributing any income to shareholders.